News

BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!

BETR is truly establishing the best possible team to take LSD and other psychedelics from experimental to major therapeutic applications.

NUMI is pleased about first-of-its-kind policy amendment that will allow legal access to evidence-based treatments to those in need before formal drug approval.

This is perhaps NUMI’s most significant development in its history.

RVV provides important update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison.

NUMI has just made history by harvesting the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.

NUMI has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.

The total gross proceeds from CMPS’s IPO were $146.6 million after sale of additional 1,125,000 ADSs.

CMPS raises $127.5 million at IPO price of $17 per ADS.

Our friends at the Non-Profit MAPS have successfully raised $30 million through the Capstone Campaign to be used to seek FDA approval of MDMA-assisted psychotherapy for PTSD.